Key points are not available for this paper at this time.
SURPASS-CVOT will provide definitive evidence as to the CV safety and efficacy of tirzepatide as compared with dulaglutide, a GLP-1 receptor agonist with established CV benefit.
Nicholls et al. (Mon,) studied this question.